SCHEMBL30452090

SCHEMBL30452090

COc1ccc(B(O)O)cc1-c1ccc2ccncc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 6/20 0.44
CYP11B2 P19099 6/20 0.44
ABL1 P00519 3/20 0.43
PRKCZ Q05513 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
PIK3CD O00329 2/20 0.40
PIK3CB P42338 2/20 0.40
PIK3CG P48736 2/20 0.40
PIK3CA P42336 1/20 0.40
PRKCI P41743 1/20 0.40
TDO2 P48775 1/20 0.40
CYP19A1 P11511 2/20 0.38
LCK P06239 1/20 0.38
CSF1R P07333 1/20 0.38
KDR P35968 1/20 0.38
MAPK14 Q16539 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24252389 1.00 CYP11B1 (0.44) CYP11B1CYP11B2ABL1PRKCZCYP1A2
SCHEMBL26771383 0.91 CYP11B1 (0.43) CYP11B1CYP11B2ABL1PRKCZCYP1A2
SCHEMBL30467740 0.82 PDGFRB (0.44) CYP1A2CYP3A4CYP2C19PDE4B
SCHEMBL24252628 0.82 PDGFRB (0.44) CYP1A2CYP3A4CYP2C19PDE4B
SCHEMBL24252955 0.80 ABL1 (0.52) CYP11B1CYP11B2ABL1PRKCZCYP1A2
SCHEMBL30451948 0.80 ABL1 (0.52) CYP11B1CYP11B2ABL1PRKCZCYP1A2
SCHEMBL24252379 0.79 DHFR (0.37) PIK3CAKDRESR1ESR2
SCHEMBL30451279 0.79 DHFR (0.37) PIK3CAKDRESR1ESR2
SCHEMBL24252941 0.78 F12 (0.60)
SCHEMBL622466 0.77 CA1 (0.55) PRKCZPIK3CDPIK3CBPIK3CGPRKCI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 CYP11B1 1061/4885CYP11B2 959/4885ABL1 4687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.